logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10098949 B1

PDFFull Text
Date of Patent:
Oct. 16, 2018

Filed:

Apr. 07, 2016

Adsorption of immunopotentiators to insoluble metal salts

Applicant:

Glaxosmithkline Biologicals SA, Rixensart, BE;

Inventors:

Manmohan Singh, Cary, NC (US);

David A. G. Skibinksi, Singapore, SG;

Tom Yao-Hsiang Wu, San Diego, CA (US);

Yongkai Li, San Diego, CA (US);

Alex Cortez, San Diego, CA (US);

Xiaoyue Zhang, San Diego, CA (US);

Yefen Zou, San Diego, CA (US);

Timothy Z. Hoffman, San Diego, CA (US);

Jianfeng Pan, San Diego, CA (US);

Kathy Yue, Minneapolis, MN (US);

Assignee:

GLAXOSMITHKLINE BIOLOGICALS S.A., , BE;

Attorney:

Joseph Schuller

Primary Examiner:

D Margaret M Seaman

Int. Cl.
CPC ...
C07D 471/04 (2006.01); A61K 39/39 (2006.01); A61K 31/661 (2006.01); A61K 31/6615 (2006.01); A61K 31/662 (2006.01); A61K 39/095 (2006.01); C07D 487/04 (2006.01); C07F 9/645 (2006.01); C07F 9/6512 (2006.01); C07F 9/6558 (2006.01); C07F 9/6561 (2006.01); A61K 39/02 (2006.01); A61K 39/05 (2006.01); A61K 39/08 (2006.01); A61K 39/09 (2006.01); A61K 39/13 (2006.01); A61K 39/145 (2006.01); A61K 39/29 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/39 (2013.01); A61K 31/661 (2013.01); A61K 31/662 (2013.01); A61K 31/6615 (2013.01); A61K 39/02 (2013.01); A61K 39/05 (2013.01); A61K 39/08 (2013.01); A61K 39/092 (2013.01); A61K 39/095 (2013.01); A61K 39/13 (2013.01); A61K 39/145 (2013.01); A61K 39/292 (2013.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01); C07F 9/645 (2013.01); C07F 9/6561 (2013.01); C07F 9/65122 (2013.01); C07F 9/65583 (2013.01); C07F 9/65616 (2013.01); A61K 2039/55505 (2013.01); A61K 2039/55511 (2013.01);
Abstract

Immunopotentiators can be adsorbed to insoluble metal salts, such as aluminum salts, to modify their pharmacokinetics, pharmacodynamics, intramuscular retention time, and/or immunostimulatory effect. Immunopotentiators are modified to introduce a moiety, such as a phosphonate group, which can mediate adsorption. These modified compounds can retain or improve their in vivo immunological activity even when delivered in an adsorbed form.

Find Patent Forward Citations

Loading…